Valuation Summit Therapeutics Inc.

Stocks

Market Closed - Nasdaq 23:00:00 19/10/2026 +03			5-day change	1st Jan Change
15.57 ^USD	+6.43%		-11.48%	-10.98%

09-22	Akeso, Inc. and Summit Therapeutics Inc. Showcase HARMONi-G11 Phase III Trial Data Featuring Ivonescimab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer At ESMO 2026	CI
09-15	Summit Therapeutics Presents Updated HarmonI Data At WCLC 2026 Demonstrating Consistent Overall Survival Results With Ivonescimab Plus Chemotherapy In Western And Asian Patients	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2023	2024	2025	2026	2027	2028
Market Cap ¹	1,436	10,512	10,021	8,770	-	-
Change	-	631.97%	-4.67%	-12.48%	-	-
Enterprise Value (EV) ¹	1,436	10,512	9,493	8,508	8,769	8,474
Change	-	631.97%	-9.69%	-10.37%	3.06%	-3.36%
P/E	-2.62x	-58.1x	-12.2x	-12.7x	-12.5x	-21.4x
PBR	-	-	20.7x	43.3x	439x	27.3x
PEG	-	0.8x	-0x	0.7x	-8.48x	0.5x
Capitalization / Revenue	-	-	-	2,984x	209x	20.4x
EV / Revenue	-	-	-	2,895x	209x	19.7x
EV / EBITDA	-	-96.9x	-11.7x	-14.8x	-15.9x	-26.8x
EV / EBIT	-	-58.8x	-11.7x	-12.6x	-12.1x	-18.7x
EV / FCF	-	-93.4x	-39.6x	-14.9x	-12.4x	-14.7x
FCF Yield	-	-1.07%	-2.52%	-6.73%	-8.09%	-6.81%
Dividend per Share ²	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-
EPS ²	-0.7828	-0.2452	-1.066	-0.8652	-0.878	-0.5124
Distribution rate	-	-	-	-	-	-
Net sales ¹	-	-	-	2.939	41.98	429.3
EBITDA ¹	-	-108.4	-810.4	-574.9	-551.9	-316.1
EBIT ¹	-	-178.8	-810.5	-674.1	-727.1	-454
Net income ¹	-486.2	-175.1	-799.5	-701	-743	-433.6
Net Debt ¹	-	-	-528.6	-261.9	-1.599	-296.3
Reference price ²	2.05	14.25	13.00	10.97	10.97	10.97
Nbr of stocks (in thousands)	700,843	737,448	771,150	799,726	-	-
Announcement Date	2/20/24 A	2/24/25 A	2/23/26 A	-	-	-

¹GBP in Million²GBP

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
SUMMIT THERAPEUTICS INC.	-12.67x	2894.86x	-14.8x	-.--%	11.7B
WUXI APPTEC CO., LTD.	18.77x	6.69x	13.41x	1.58%	65B
LONZA GROUP AG	35.3x	6.27x	18.74x	0.92%	51.2B
ARGENX SE	27.56x	7.53x	23.83x	0.05%	51.19B
IQVIA HOLDINGS INC.	34.01x	3.32x	14.33x	-.--%	43.93B
BEONE MEDICINES AG	48.9x	5.59x	30.73x	-.--%	41.96B
REVOLUTION MEDICINES, INC.	-18.47x	189.62x	-19.51x	-.--%	38.14B
CELLTRION, INC.	28.97x	8.21x	21.25x	0.37%	33.24B
WUXI BIOLOGICS (CAYMAN) INC.	29.19x	6.17x	16.01x	-.--%	25.2B
GENMAB A/S	30.74x	5.69x	19.09x	-.--%	22.5B
Average	22.23x	313.40x	12.31x	0.29%	38.41B
Weighted average by Cap.	24.79x	112.43x	14.56x	0.43%